Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine

Elizbeth Miller, Nicholas Andrews, Pauline A. Waight, Mary Slack, Robert George

Research output: Contribution to journalArticlepeer-review

160 Citations (Scopus)

Abstract

Efficacy of the new serotypes in the 13-valent pneumococcal conjugate vaccine (PCV13) against invasive pneumococcal disease (IPD) was based on a putative correlate of protection. In England and Wales, PCV13 replaced PCV7 in the 2, 4, and 13 month schedule in April 2010. Using non-vaccine type IPD cases as controls, we estimated vaccine effectiveness (VE) for the new serotypes. Among 166 IPD cases in PCV13 eligible children reported by July 2011 with known serotype and vaccination status, VE for 2 doses under a year was 78% (95% confidence interval -18% to 96%) and 77% (38-91%) for one dose over a year. VE for 7F and 19A was 76% (21-93%) and 70% (10-90%) respectively for ≥one dose. VE for serotypes 1 and 3 was 62% and 66% respectively although confidence intervals spanned zero. IPD due to PCV13-only serotypes halved in children under 2 years in the study period.

Original languageEnglish
Pages (from-to)9127-9131
Number of pages5
JournalVaccine
Volume29
Issue number49
DOIs
Publication statusPublished - 15 Nov 2011

Keywords

  • 13-Valent vaccine
  • Invasive pneumococcal disease
  • Pneumococcal conjugate vaccine
  • Vaccine effectiveness

Fingerprint

Dive into the research topics of 'Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine'. Together they form a unique fingerprint.

Cite this